Screener
ImmunityBio, Inc. IBRX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease liabilities | 4,690 | 4,291 |
| Operating lease liabilities – related parties | 2,936 | 3,244 |
| Due to related parties | 930 | 403 |
| Total current liabilities | 67,952 | 61,754 |
| Related-party convertible note payable, at fair value (Note 14) | 678,386 | 477,093 |
| Revenue interest liability (Note 13) | 404,299 | 324,615 |
| Operating lease liabilities, less current portion | 20,062 | 19,732 |
| Operating lease liabilities, less current portion – related parties | 13,085 | 13,715 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s total current liabilities?
- ImmunityBio, Inc. (IBRX) reported total current liabilities of $67.95M in Q1 2026.
- How has ImmunityBio, Inc.'s total current liabilities changed year-over-year?
- ImmunityBio, Inc.'s total current liabilities increased by 38.1% year-over-year, from $49.21M to $67.95M.
- What is the long-term trend for ImmunityBio, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s total current liabilities has grown at a -1.9% compound annual growth rate (CAGR), from $68.13M to $61.75M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about ImmunityBio, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude